Lodem

Quick links to important sections

Lodem

Method of action: Hypoglycemic

Treatment option: Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lodem

What is Lodem?

Lodem is a pharmacological treatment used primarily in the management of Parkinson's disease and certain Parkinson-like symptoms. It belongs to a class of medications known as decarboxylase inhibitors. It is not typically used on its own; rather, it is designed to be administered in combination with levodopa.

Mechanism of Action

To understand how Lodem works, it is necessary to look at how the body processes levodopa. Levodopa is a precursor to dopamine, the neurotransmitter that is deficient in individuals with Parkinson's disease. When levodopa is taken, it travels through the bloodstream with the goal of reaching the brain, where it can be converted into dopamine.

However, without a protector, much of the levodopa is converted into dopamine prematurely in the bloodstream before it ever crosses the blood-brain barrier. This peripheral conversion can lead to various side effects and reduces the amount of medication actually reaching the brain. Lodem works by inhibiting the enzyme responsible for this premature conversion. Because Lodem itself cannot enter the brain, it only prevents the breakdown of levodopa in the rest of the body, allowing more of the primary medication to reach its intended destination in the central nervous system.

Therapeutic Role

The integration of Lodem into a treatment regimen serves two main purposes:

  • Efficiency: It increases the bioavailability of levodopa within the brain, often allowing for more effective management of motor symptoms such as tremors, stiffness, and slowness of movement.
  • Side Effect Management: By preventing the accumulation of dopamine in the peripheral circulatory system, it helps reduce certain systemic reactions that occur when dopamine levels rise outside of the brain.

Lodem is utilized to help stabilize the therapeutic response to levodopa, providing a more consistent level of the medication for the management of chronic neurological symptoms.

What side effects are possible with Lodem?

Official Safety Profile and Adverse Reactions

The safety profile for Lodem (Gliquidone), a sulfonylurea, is structured around adverse reactions categorized by frequency and the body system affected, according to government regulatory documents. The most critical, class-specific safety concern is hypoglycaemia (low blood sugar), which is officially noted to be more likely during the initiation of treatment or following dose increases.

Adverse reactions are grouped into System-Organ Classes (SOCs), with effects on Metabolism and Nutrition (hypoglycaemia), Gastrointestinal Disorders (e.g., nausea, vomiting, diarrhoea, constipation), and Nervous System Disorders (headache, dizziness) commonly documented.

Documented Serious Reactions and Restrictions

While most effects are considered non-serious, the official prescribing information documents rare but serious adverse reactions, including severe hypoglycaemia, and very rare haematological effects such as agranulocytosis and cholestatic jaundice.

Specific patient conditions are listed as contraindications where the medicine must not be used due to safety concerns. These include Type 1 Diabetes Mellitus, Diabetic ketoacidosis, and Severe Hepatic Impairment.

Population-Specific Safety Considerations

A key safety characteristic of Gliquidone noted in official sources is its primary elimination pathway through biliary excretion (via bile and feces) with minimal renal clearance. This pharmacological characteristic is a specific consideration for its use in patients with impaired renal function.

Overdose and Emergency Response

Lodem (Gliquidone) overdose is strictly defined by the risk of profound and prolonged hypoglycemia, which is classified in regulatory documents as a potentially life-threatening event. Overdose may present with a spectrum of documented clinical signs, beginning with autonomic symptoms such as trembling, diaphoresis (sweating), and palpitations. These manifestations can progress to more severe Central Nervous System (CNS) effects, including confusion, lethargy, seizures, and potentially coma.

Emergency medical attention is required immediately for any patient experiencing symptomatic hypoglycemia following Lodem exposure, or for all cases of suspected intentional overdose. Official guidance mandates that these situations require hospital admission and continuous observation. Supportive management protocols documented by regulatory authorities include the administration of an intravenous dextrose bolus to correct the low blood sugar, followed by a sustained infusion. The use of Octreotide is described as an antidote in management protocols to inhibit further insulin release.

Monitoring requirements specify that patients should undergo frequent blood glucose assessment and must be observed for a minimum period of 12 hours after discontinuation of supportive therapies to exclude the risk of recurrent hypoglycemia. The official labeling notes that the elderly and patients with underlying hepatic or renal insufficiency may face increased risk or severity of effects.

Therapeutic Uses of Lodem

What Lodem Treats: Main Uses and Benefits

Lodem is commonly used across conditions presenting with acute episodes. It is used for managing signs and symptoms that create noticeable physiological strain associated with chronic conditions characterized by periods of heightened symptoms, as well as for the short-term relief of symptoms related to physical discomfort.

Lodem is considered relevant for managing specific inflammatory joint conditions involving inflammatory or irritative processes. This medication is commonly used to help with the discomfort, stiffness, and inflammation linked to osteoarthritis and rheumatoid arthritis. It is also relevant for easing symptoms associated with acute or episodic changes.

In contexts involving heightened systemic burden, Lodem assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations. As part of supportive symptom management, it is commonly used to help with easing the overall symptom load. For many patients, the role it plays is simple: “It helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Used for Managing Symptom Clusters Lodem may be part of symptomatic management for symptoms that become more disruptive during flare-ups and other episodes of heightened physiological activity.

Regulatory References

  1. NIH MedlinePlus overview on Etodolac

Eligibility and Restrictions for Use

Lodem, which contains the active substance lodenafil, is a phosphodiesterase type 5 (PDE5) inhibitor primarily used for the treatment of erectile dysfunction (ED) in adult men. Its use is generally considered safe when prescribed appropriately.

Contraindications (Who Should Not Use Lodem)

Lodem is contraindicated in patients with certain medical conditions or those taking specific medications, as the combination can lead to severe health risks. The primary absolute contraindication is the concurrent use of any form of organic nitrates or nitric oxide donors (such as nitroglycerin), as this can cause a potentially life-threatening drop in blood pressure.

Additionally, Lodem should not be used in patients with:

  • A history of heart attack (myocardial infarction), stroke, or life-threatening arrhythmias within the past six months.
  • Uncontrolled or severe hypotension (low blood pressure) or hypertension (high blood pressure).
  • Severe liver impairment or severe renal impairment (kidney disease, including those receiving hemodialysis).
  • Known hypersensitivity or allergic reaction to lodenafil or any components of the tablet.

Precautions (Use with Caution)

Caution and potential dose adjustment are necessary for patients with certain conditions or who are taking interacting medications. These include individuals:

  • Taking alpha-blockers (often for high blood pressure or prostate issues) due to the risk of symptomatic low blood pressure.
  • Taking certain CYP3A4 inhibitors (such as some antibiotics and antifungals), which can increase Lodem levels in the blood.
  • With pre-existing cardiovascular conditions, a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), or conditions that may predispose them to priapism (a prolonged, painful erection).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lodem (Gliquidone) has officially documented interaction patterns structured around its metabolic clearance and pharmacodynamic action, as noted in regulatory prescribing information.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Classes Official Regulatory Outcome
Metabolic (CYP3A4) CYP3A4 Inhibitors (e.g., Amiodarone, Atovaquone, Azelastine) May decrease Lodem's metabolism, increasing systemic exposure and hypoglycemia risk.
Transporter/Metabolic Tofacitinib Lodem reduces Tofacitinib clearance, leading to increased Tofacitinib AUC and Cmax.
Pharmacodynamic (Additive) Other antidiabetic agents (e.g., Albiglutide, Sitagliptin) Additive effect, resulting in a heightened risk of hypoglycemia.
Pharmacodynamic (Antagonistic) Corticosteroids, Thiazide Diuretics May reduce Lodem’s therapeutic efficacy, resulting in a risk of hyperglycemia.
Protein Binding Highly protein-bound NSAIDs (e.g., Aceclofenac) May cause a transient increase in unbound (free) plasma concentration of Lodem.

Restrictions and Population Notes

The regulatory profile includes a constraint regarding Alcohol (Ethanol), which may either potentiate the hypoglycemic effect or induce a disulfiram-like reaction. Official documentation also provides caution that interaction effects may be heightened in severe hepatic impairment, as Lodem's primary reliance on biliary excretion for clearance can be compromised. No combinations are formally specified as contraindicated.

Mechanism of Action

Lodem, chemically identified as Lodoxamide, functions as a mast cell stabilizer with its primary biological target being the mast cell membrane. The drug's interaction type is postulated to involve prevention of calcium ion influx into mast cells following specific stimuli. This action mechanically modifies cellular processes by stabilizing the mast cell membrane, thereby inhibiting the molecular and intracellular pathway of degranulation. The subsequent downstream cascade is the reduced release of pro-inflammatory mediators, including histamine and various chemoattractant factors, from the intracellular storage granules into the extracellular space. This local cellular modulation results in a system-level physiological consequence of decreased local tissue inflammatory signaling and vascular permeability in the targeted peripheral tissues.

Dosage and Administration Information

How to Use Lodem: Official Administration Guidelines

Lodem is an oral medication with usage protocols defined to ensure consistent blood glucose management protocols for Type 2 Diabetes. The standard route of administration is oral, delivered as a tablet.

Dosing and Frequency

The administration regimen is characterized by a once-daily frequency, which is specified to be taken at breakfast time (immediately before or during the first meal of the day). This precise timing is a fundamental part of its use, and the tablet must be swallowed whole.

Treatment typically begins with an initial daily dose of 30 mg. The amount is subsequently adjusted based on the individual patient's metabolic response. The maintenance dose range generally spans from 30 mg up to a maximum recommended dose of 120 mg daily. Adjustments to the dose should be made gradually, usually at intervals of no less than one month, to allow the body to stabilize before proceeding to the next titration step.

Administration Constraints and Special Populations

A specific usage constraint relates to patients with renal impairment. Because Gliquidone is primarily eliminated through the bile rather than the kidneys, no dose adjustment is typically necessary for mild to moderate renal insufficiency. However, the guidance for this group often specifies initiating treatment at the minimum daily starting dose of 30 mg.

Furthermore, if a daily dose is forgotten, the instructions dictate that the dose taken the next day must not be increased to compensate, maintaining the integrity of the prescribed regimen.

Recent Clinical Evidence

Research Evidence and Clinical Study Overview

This section summarizes the structure of the clinical evaluation for Lodem (Gliquidone), focusing on the types of studies that exist, the populations they examined, and the consistency of the evidence, as reported by regulatory and peer-reviewed scientific sources. The findings describe group patterns and research limitations, not individual predictions or outcomes.


Evidence for Use in Type 2 Diabetes Mellitus

The research primarily involves Randomized Controlled Trials (RCTs) and various comparative clinical studies. This research was conducted to understand its role in influencing elevated blood sugar levels in adult patients with Type 2 Diabetes who needed assistance beyond diet and lifestyle changes.

Studies monitored changes in key biomarkers, focusing on the average long-term blood sugar marker, Glycated Hemoglobin (HbA1c), as well as shifts in Fasting Blood Glucose (FBG) measurements. Studies also monitored the frequency of low blood sugar, or hypoglycemia, as a monitored outcome across the observed populations. Research highlights changes measured during the study period, with findings describing measured patterns in blood sugar biomarkers.


Evidence in Patients with Coexisting Kidney Function Impairment

A key area of research examined populations with coexisting mild to moderate renal insufficiency (impaired kidney function) with Type 2 Diabetes. This evidence base includes specialized pharmacokinetic studies that analyzed the drug's properties related to its elimination from the body.

Pharmacokinetic research describes patterns related to drug clearance, noting its primary elimination pathway is biliary excretion (via bile and feces) rather than renal excretion. This characteristic was studied in comparative clinical trials involving patients with varying degrees of kidney function. Clinical studies in populations with mild to moderate renal impairment described patterns in the studied blood sugar biomarkers, and these findings were observed in the research for this specific subgroup.


Study Quality and Evidence Gaps

The regulatory and scientific consensus suggests that evidence quality varies across studies. While the core evidence confirming its classification and action is well-established, many older trials that established the initial profile may have methodological limitations when assessed by modern clinical trial standards. Limited data are available for long-term patient-centric endpoints, and comparative evidence against some of the newer classes of oral antidiabetic agents is also currently lacking in the broader research landscape.

Frequently Asked Questions (FAQ)

Common questions about Lodem (FAQ)

Q: What is Lodem actually used for, besides the main thing?

A: The official regulatory documentation indicates that Lodem is solely approved for the management of Type 2 Diabetes Mellitus. Its purpose is to help lower and control elevated blood glucose levels in adults. No other medical conditions or uses are listed on the main regulatory label.


Q: Is Lodem the same type of medicine as [similar common drug name]?

A: Lodem is classified as a sulfonylurea, which is a type of oral drug used to treat high blood sugar. The active ingredient, Gliquidone, belongs to the category of oral hypoglycemic agents. This classification defines the general mechanism by which the medicine works within the body.


Q: What's the difference between Lodem and other drugs that treat the same thing?

A: Official documents note that a key characteristic of Lodem is its primary method of elimination from the body. It is mainly cleared through biliary excretion (via bile and feces) rather than by the kidneys, which distinguishes it from several older medications in the same class.


Q: Can Lodem make you feel tired or drowsy during the day?

A: The official safety profile documents effects on the Nervous System Disorders, which commonly include dizziness and headache. Awareness of these effects is important, as they may potentially impact daily function.


Q: Are there any specific foods I should avoid when taking Lodem?

A: Regulatory information states that the medication must be taken at breakfast time (with the first meal of the day). Furthermore, official documents specify a constraint and caution regarding the consumption of Alcohol (Ethanol).


Q: Can older people use Lodem without higher risk?

A: While the official label does not specify an age restriction, it addresses a common concern in older populations regarding kidney function. Official information states that for patients who may have underlying or age-related impaired renal function, treatment may be initiated at the lowest approved starting dose.


Q: Is Lodem safe for teenagers or young adults?

A: The official regulatory label and the clinical research summary for Lodem describe the medication's approved use and evidence solely in adult patients with Type 2 Diabetes Mellitus. The available data does not cover use in pediatric or adolescent populations.


Q: How does the way Lodem works compare to older treatments?

A: Lodem is categorized as an insulin secretagogue. This means its core mechanism is to prompt the pancreatic beta cells to release pre-formed insulin into the bloodstream, helping to lower blood sugar levels.


Q: Can I drive or operate machinery while taking Lodem?

A: The official safety profile includes warnings about documented Nervous System Disorders and the critical risk of hypoglycaemia (low blood sugar). These effects may potentially impair concentration and reaction time, and this may be a factor when considering the ability to perform skilled tasks like driving or operating machinery.


Q: What are the signs that Lodem might not be right for me?

A: Official regulatory warnings list specific patient conditions where the medicine must not be used. These include Type 1 Diabetes Mellitus, Diabetic ketoacidosis, and severe Hepatic Impairment (liver disease).


Q: Is Lodem a scheduled or controlled substance?

A: Lodem is officially classified as a Prescription Only Medicine (POM). This status means it is only dispensed with a valid prescription from a licensed healthcare provider and is not available over the counter.


Q: Does Lodem require a special prescription or monitoring?

A: The drug is a Prescription Only Medicine. Official prescribing information states that subsequent dose adjustments after initiation are determined based on the individual patient's metabolic response over time.


Q: What does 'contraindication' mean for Lodem users?

A: A contraindication is a specific term used in medicine to identify patient conditions or concurrent uses of other drugs where the use of Lodem is officially deemed inadvisable. Use in these situations is officially advised against due to the potential for adverse outcomes or severe harm.


Q: Do I need to change my diet while on Lodem?

A: Regulatory guidelines for the medication's use require it to be taken once-daily at breakfast time (immediately before or during the first meal of the day). This specific timing is a required condition for administration as outlined in the regulatory guidelines.


Q: Are there any concerns about using Lodem long-term?

A: The clinical evidence summary indicates that while the drug's core classification and action are established, regulatory reviews have noted that limited data is available concerning long-term, patient-centric outcomes.


Q: Has Lodem been studied in people with other health conditions?

A: The primary clinical research base involves adult patients with Type 2 Diabetes. Specialized studies have also examined patient groups with coexisting mild to moderate renal insufficiency (impaired kidney function).


Q: Can I take pain relievers like ibuprofen with Lodem?

A: Official interaction documents warn that highly protein-bound Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the unbound plasma concentration of the active ingredient. The potential for this effect suggests the need for specific consideration when using medicines in this drug class.


Q: Is it normal to feel [vague symptom] when you first start Lodem?

A: The official safety profile explicitly notes a common pattern for the most critical safety concern: hypoglycaemia (low blood sugar) is more likely to occur during the initiation of treatment or following dose increases.


Q: What non-prescription drugs are known to interact with Lodem?

A: The regulatory profile specifies a constraint regarding Alcohol (Ethanol). Consumption may either intensify the low blood sugar effect or potentially trigger a disulfiram-like reaction.

How should Lodem be stored and disposed of?

How to Store and Dispose of Lodem?

Authorities specify strict requirements for storing and disposing of prescription medication to maintain stability and prevent accidental ingestion.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20°C to 25°C (68°F to 77°F).
Protection Keep Lodem in its original, tightly closed container, protected from excessive heat, light, and moisture.
Security Always keep the container in a secure location, out of the sight and reach of children and pets.

Disposal Requirements

The preferred method for disposing of unused or expired Lodem is through an official drug take-back program. If a program is not available and the medication is not on a specific flush list, mix it with an unappealing substance, place the mixture in a sealed container, and discard it in the household trash. Before disposing of the empty container, all personal identifying information must be permanently removed from the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lodem found in:

A-Z Index: